Relationship between atorvastatin dose and the harm caused by torcetrapib

Development of the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, was halted after the ILLUMINATE trial revealed an increase in both all-cause mortality (ACM) and major cardiovascular events (MCVEs) associated with its use. We now report that the harm caused by torcetrapib was con...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Barter, Philip J., Rye, Kerry-Anne, Beltangady, Mohan S., Ports, William C., Duggan, William T., Boekholdt, S. Matthijs, DeMicco, David A., Kastelein, John J. P., Shear, Charles L.
Format: Artigo
Jezik:Inglês
Izdano: The American Society for Biochemistry and Molecular Biology 2012
Teme:
Patient-Oriented and Epidemiological Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3466012/
https://ncbi.nlm.nih.gov/pubmed/22941786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.P026328
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki